MTBVAC疫苗在新生小鼠中是安全的、具有免疫原性的，并能赋予针对结核分枝杆菌的保护效力。
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.
作者信息
Aguilo Nacho, Uranga Santiago, Marinova Dessislava, Monzon Marta, Badiola Juan, Martin Carlos
机构信息
Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Research Centre for Encephalopathies and Transmissible Emerging Diseases, Universidad de Zaragoza, 50013 Zaragoza, Spain.
出版信息
Tuberculosis (Edinb). 2016 Jan;96:71-4. doi: 10.1016/j.tube.2015.10.010. Epub 2015 Nov 30.
Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
开发新型、更有效的抗结核病（TB）预防性疫苗对于在2050年实现结核病消除至关重要，这是本世纪千年发展目标（MDG）之一。MTBVAC是第一种也是唯一一种基于结核分枝杆菌人分离株的减毒活疫苗，作为卡介苗（BCG）替代策略用于新生儿，已进入成人首次人体临床试验。在这项研究中，我们在新生C57/BL6小鼠模型中对MTBVAC的安全性、免疫原性和保护效力进行了表征。我们的数据清楚地表明，MTBVAC对新生小鼠是安全的，并且不影响动物生长或器官发育。此外，与卡介苗相比，出生时接种MTBVAC的小鼠表现出增强的免疫原性和对结核分枝杆菌攻击的更好保护作用。
Zotero 插件